A PARADIGM ADVANCING TOXICITY TESTING OF NANOMATERIALS IN THE 21 st CENTURY AND QSAR MODELS DEVELOPMENT. David Y. Lai. U.S. EPA, Washington, DC. Feb. 9,

Slides:



Advertisements
Similar presentations
Workplace exposure to nanoparticles. Workplace exposure to nanoparticles Aims  To provide the Risk Observatory target audience with a comprehensive picture.
Advertisements

Dosimetry in Risk Assessment and a bit More Mel Andersen McKim Conference QSAR and Aquatic Toxicology & Risk Assessment June 27-29, 2006.
UNEP Advisory Group Meeting Geneva, Switzerland December 12, 2014
© 2004 Prof Roland Clift NANOTECHNOLOGY Professor Roland Clift, Centre for Environmental Strategy, University of Surrey, GUILDFORD, Surrey GU2 7XH, UK.
National Pesticide Program A New Toxicology Testing Paradigm: Meeting Common Needs Steven Bradbury, Director Environmental Fate and Effects Division Office.
1 Development & Evaluation of Ecotoxicity Predictive Tools EPA Development Team Regional Stakeholder Meetings January 11-22, 2010.
ONAMI’s - Safer Nanomaterials and Nanomanufacturing Initiative Recommendations for the FDA Nanotechnology Task Force Stacey Harper.
Effects of Etoposide on the Apoptosis of HL-60 Cells Stefanos F. Haddad a, Glaucia V. Faheina-Martins b,c, Demetrius A. M. Araújo b,c a Department of Biology,
What Do Toxicologists Do?
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
IANH and ISO Proposals C. Michael Garner Garner Nanotechnology Solutions Visiting Scholar Stanford University EE Department.
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
Impacts of Manufactured Nanomaterials on Human Health and the Environment – A Focus on Nanoparticulate Aerosol and Atmospherically Processed Nanoparticulate.
Considerations for Characterizing the Potential Health Effects from Exposure to Nanomaterials David B. Warheit, PhD. DuPont Haskell Laboratory Newark,
N ANOPARTICLES IN BIOLOGY AND MEDICINE Antti Rautiainen KE Nanopartikkelit.
Nanomaterials: Potential impact on human health Paul J.A. Borm Paris- OECD- june 7 th 2005.
Abiotic/Biotic Interface Workshop NIH April 8, 2009.
Luděk Bláha, PřF MU, RECETOX BIOMARKERS AND TOXICITY MECHANISMS 13 – BIOMARKERS Summary and final notes.
Criteria for Screens— Review of the EDSTAC Recommendations Presentation to the EDMVS July 23, 2002.
ILSI Risk Science Institute Acrylamide Toxicity: Research to Address Key Data Gaps Presented by Dr. Stephen S. Olin ILSI Risk Science Institute.
TCEQ/NUATRC Air Toxics Workshop: Session V – Human Health Effects Nathan Pechacek, M.S. Toxicology Section Texas Commission on Environmental Quality
Accident Prevention Manual for Business & Industry: Engineering & Technology 13th edition National Safety Council Compiled by Dr. S.D. Allen Iske, Associate.
Knowledgebase Creation & Systems Biology: A new prospect in discovery informatics S.Shriram, Siri Technologies (Cytogenomics), Bangalore S.Shriram, Siri.
Nanomaterial Registry: Minimal Information Standards for Well-Characterized Nanomaterials in Environmental and Biological Studies Michele L. Ostraat April.
Shankar Subramaniam University of California at San Diego Data to Biology.
Chapter 13. The Impact of Genomics on Antimicrobial Drug Discovery and Toxicology CBBL - Young-sik Sohn-
GTL Facilities Computing Infrastructure for 21 st Century Systems Biology Ed Uberbacher ORNL & Mike Colvin LLNL.
 Basic Definition:  Basic Definition: Technology of building or creating products such as electronic circuits from single atoms and molecules Deals.
Presentation 3: Are nanomaterials a worker health and safety risk?
Betraying Paracelsus, Ignoring Newton: A Flaw in the Nanotoxicology Paradigm Justin Teeguarden, PHD, DABT [Paul Hinderliter, Joel Pounds, Brian Thrall,,
Presentation 3: What is nano?
High Throughput Genotoxicity Profiling of the US EPA ToxCast TM Chemical Library S Little 1, AW Knight 2, L Birrell 2, G Akerman 3, N McCarroll 3, D Dix.
Luděk Bláha, PřF MU, RECETOX BIOMARKERS AND TOXICITY MECHANISMS 01 - INTRODUCTION.
The US Tox21 Collaboration: Advances Made and Lessons Learned
IISP Workshop Gaithersburg, Maryland May , 2006 Nanotechnology Initiative Paul F. Wambach, CIH Industrial Hygienist Office of Epidemiology and Health.
SAFETY PRECAUTIONS & TOXICITY RESEARCH NANOTECHNOLOGY.
New or increasing occupational exposure to chemical and biological agents Gérard Lasfargues Deputy Director General, Anses.
Principal component analysis Treated Vehicle Treated Vehicle.
Click to edit Master title style Click to edit Master text styles –Second level Third level –Fourth level »Fifth level Office of Research and Development.
Center for the Environmental Implications of Nanotechology Program Solicitation NSF Preliminary Proposal Due: December 10, 2007 National Science.
1 Selecting Materials for Understanding the Human Health and Ecological Risks of Nanomaterials Considerations and Approach Justin Teeguarden, PhD., DABT.
THE NEED FOR NANOMATERIAL EVALUATION IN A PHYSIOLOGICALLY RELEVANT MODEL: CONNECTING ENVIRONMENTAL VARIABLES AND NM BEHAVIOR TO TOXICOLOGICAL RESPONSES.
Toxicity analysis of PbS QDs using nano-sized vesicles (exosome) secreted from HEK293 cells Eunjoo Kim, Ph. D. Daegu Gyeongbuk Institute of Science and.
Cellular Toxicity of Carbon - based Nanomaterials Nano Letters, 2006, 6 (6), pp 1121–1125 Electrical Engineering and Computer Sciences University of California,
TOXICOGENOMICS.
QSAR in CANCER ASSESSMENT PURPOSE and AGENDA Gilman Veith Duluth MN May 19-21, 2010.
Office of Research and Development National Center for Computational Toxicology Amy Wang National Center for Computational Toxicology The views expressed.
1 OSHA’s Approach to Nanotechnology: Developing a Searchable "Health Effects Matrix" Database for Nanomaterials Utilizing Existing Published Data Janet.
Air Pollution Research Group Analysis of 1999 TRI Data to Identify High Environmental Risk Areas of Ohio by Amit Joshi.
NUATRC/TCEQ Air Toxics Workshop October Air Toxics Air Toxics: What We Know, What we Don’t Know, and What We Need to Know Human Health Effects –
1 1 EPA Nanotechnology Research Program – LCA Considerations Jeff Morris National Program Director for Nanotechnology 5 November 2009.
McKim Workshop on Strategic Approaches for Reducing Data Redundancy in Cancer Assessment Duluth, MN, USA 19 May, 2010.
The Future of Chemical Toxicity Testing in the U.S.
McKim Conference on Predictive Toxicology The Inn of Lake Superior Duluth, Minnesota September 25-27, 2007 Toxicity Pathways as an Organizing Concept Gilman.
Perspective on the current state-of-knowledge of mode of action as it relates to the dose response assessment of cancer and noncancer toxicity Jennifer.
Toxic effects Acute / chronic Reversible / irreversible Immediate / delayed Idiosyncratic - hypersensitivity Local / systemic Target organs.
Office of Research and Development National Center for Environmental Assessment Human Health Risk Assessment and Information for SRP July 28, 2009 Reeder.
Importance of surface modification of silica nanoparticles, exposure conditions and particle uptake for cytokine responses in epithelial lung cells. NANOMAT.
Health and environmental impacts of nanoparticles: too early for a risk assessment framework? Prof Jim Bridges Emeritus Professor of Toxicology and Environmental.
Key Concepts on Health Risk Assessment of Chemical Mixtures.
Nanosafety ISO TC 229 Nanotechnologies Standardization in the field of nanotechnologies that includes either or both of the following:  1. Understanding.
Importance of size and surface area with respect to effect of particles on cytokine release in lung cells NANOMAT Conference 2009 Lillehammer, 18 may 2009.
FIFRA SAP Meeting February 2, 2010
Z. Gajda-Meissner, M. Hartl, T. F. Fernandes
Decision Contexts in a Changing Toxicology Paradigm
پیشگیری و کنترل خطرات بهداشتی و ایمنی نانومواد
How Can Standards for Graphene Nanomaterials Support TSCA Compliance?
Using Mode of Action to Reduce Uncertainty in Risk Estimates
RSESS March 18, 2008 Robert Osterberg
Presentation transcript:

A PARADIGM ADVANCING TOXICITY TESTING OF NANOMATERIALS IN THE 21 st CENTURY AND QSAR MODELS DEVELOPMENT. David Y. Lai. U.S. EPA, Washington, DC. Feb. 9, 2012 NCI caBIG ® Nanotechnology Working Group

Complexity of Nanomaterials (NM) NM are of varying : Chemical composition Size/Dimension Agglomeration/Aggregation state Shape Surface area Surface chemistry/reactivity Crystallinity Other physicochemical properties

Shape Agglomerate/ Aggregate Size Surface area Surface energy Deposition & Clearance kinetics Crystallinity Chemical composition Surface reactivity Biological Effects (e.g., cytotoxicity, inflammation, cancer) Biopersistence Surface chemistry/ charge Solubility & Durability Engineered Nanomateria Physical factors Biopersistence Chemical factors Surface coating Chemical/ metal ions

Issues on Chronic Inhalation Toxicity Study Very costly Use large number of animals Take long time to complete Large quantity of materials to generate aerosol Require sophisticated exposure facilities, and are technically difficult

In vitro Assays Advantages: Rapid and inexpensive Allow specific biological and mechanistic pathways to be tested under controlled conditions No animal studies needed if an in vitro assay/a battery of in vitro assays can be used for hazard identification

Issues on In Vitro Assays of NM Adsorption of proteins: may confound endpoints that rely on the measurement of a protein (e.g., LDH, formazan) produced but removed from the supernatant -- false negative Interference of assays rely on measurement of a colored or fluorescent product –false positive & false negative Culture medium effects: on physicochemical characteristics and particokinetics – false positive and false negative

HTS Assays Proposed by NRC for toxicity testing of chemicals in the 21 st Century A powerful tool for monitoring the pattern of cellular pertubations in specific pathways – shifts in gene expression: providing “genetic fingerprints” elicited in vitro and in vivo Can assess the biological activity of larger numbers of NM with different pc properties by multiple cell-based assays, in multiple cell types, and at multiple doses Toxicogenomics and other technologies (e.g., proteomics) – the only possible solution to deal effectively with issues involved in safety assessment of diverse types of NM

A Paradigm advancing “Toxicity Testing of Nanomaterials (NM) in the 21 st Century” In this proposed paradigm, the health hazards and molecular mechanisms of various classes/subclasses of NM are evaluated by using reference NM, short-term in vivo animal studies in conjunction with high-throughput screenings and mechanism-based short-term in vitro assays. The toxicological properties of a small number of well characterized reference materials of each class/subclass of NM are first characterized by short-term in vivo studies (e.g., 28- or 90-day inhalation) in rodents. In vivo and in vitro high-throughput genomics and/or proteomics studies are then performed to investigate the underlying molecular mechanisms/toxicity pathways and biomarkers of the toxic responses. Mechanism-based short-term in vitro assays in appropriate cell lines are also conducted to aid in elucidation or interpretation of mechanisms, toxicity pathways and biomarkers data derived from the in vivo studies.

A Paradigm advancing “Toxicity Testing of Nanomaterials (NM) in the 21 st Century” (cont.,) Once these mechanistic data on reference NM are obtained, they can be used to benchmark and predict the effects and hazard potential of a particular NM belonging to the same class/subclass by comparing data of their in vitro high-throughput and mechanism-based short-term in vitro assays. With well-designed experiments, testing NM of varying/selected physicochemical parameters may be able to identify the physicochemical parameters contributing to toxicity. When the physicochemical parameter(s) and the cut-off values of the parameter(s) contributing to toxicity are identified, knowledge rule-based or other SAR computer model systems can be developed for predicting the hazard potential of NM based on property-activity relationships.

Computerized predictive models development Carbon-based Metal-basedOthers Fullerenes Carbon nanotubes Others (e.g., carbon black ) Metals (e.g.,Ag, Au, Cu, QD) Metal oxides (e.g.,TiO 2, ZnO, CeO 2 ) Dendrimers, nanoclays, polystyrene, etc. Well-characterized reference materials Nanoparticles with varying/ selected physicochemical characteristics Short-term in vivo studies and high- throughput genomics/ proteomics in vivo assays High- throughput genomics/proteom ics in vitro assays Mechanism- based short- term in vitro assays Characterize toxicological effects, identify key toxicity pathways/ biomarkers and molecular mechanisms underlying the effects of reference materials with high and low toxicity Evaluate toxicity/hazard potential by comparing high-throughput and short- term in vitro assays data with those of reference materials Identify physicochemical parameter(s) and cut-off values of parameter(s) that are contributing to toxicity PBPK and dose- response modelings for quantitative risk assessment Hazard ranking and prioritizing for further testing

An Example -- CNT (1)Characterize the toxicological effects of well characterized reference nanomaterials (e.g., multi-wall carbon nanotubes, MWCNT) by short-term in vivo animal study (e.g., 28- or 90-day inhalation toxicity studies in rats) Purified MWCNT (Diameter : nm; Length : > 10 µm) Purified MWCNT (Diameter : nm; Length : < 5 µm) Purified MWCNT (Diameter : nm; Length : >10 µm)

(2) Investigate the molecular mechanisms underlying the effects and identify key toxicity pathway/biomarkers by high- throughput assays. In vivo and in vitro high-throughput genomics and/or proteomics studies of alveolar macrophages, epithelial and mesothelioma cells exposed to MWCNT are performed to investigate the underlying molecular mechanisms/toxicity pathways and biomarkers of the toxic responses.

(3) Test the reference nanomaterials (MWCNT) by mechanism-based short-term in vitro assays. Mechanism-based short-term in vitro assays (DCFDA assays for oxidative stress/ROS, ELIZA assay for cytokines, comet assays for DNA damage, TUNEL assays for apoptosis, etc.) in human/rat alveolar macrophages, epithelial and mesothelioma cells are conducted to aid in elucidation or interpretation of mechanisms, toxicity pathways and biomarkers data derived from the high-throughput genomic/proteomics studies.

(4) Evaluate the potential hazard/risk of a particular MWCNT by conducting high-throughput in vitro assays and mechanism-based short-term in vitro assays (in human/rat alveolar macrophages, epithelial and mesothelioma cells) and comparing data with those of the three reference materials (MWCNTs). (5) Evaluate the potential hazard/risk of MWCNT of varying physicochemical parameters (e.g. diameter, length, aspect ratio, agglomeration state) by conducting high- throughput in vitro assays and mechanism-based short- term in vitro assays and comparing data with those of the three reference materials (MWCNTs).

(6) Identify physicochemical parameter(s) and cut-off values of parameter(s) that contribute to toxicity of MWCNT. (7) Develop computer models to predict toxicity of MWCNT based on property-activity relationships. Once the physicochemical parameter(s) and the cut-off values of the parameter(s) [e.g. length, diameter, agglomeration state, density] that contribute to toxicity are identified, knowledge rule-based or other SAR computer model systems can be developed to predict the hazard potential of particular MWCNT.

References Gou NA, Onnis-Hayden A, Gu AZ. (2010). Mechanistic toxicity assessment of nanomaterials by whole-cell-array stress genes expression analysis. Environ Sci Tech, 44: Haniu H, Matsuda Y, Takeuchi K, Kim YA, Hayashi T, Endo M. (2010). Proteomic-based safety evaluation of multi-walled carbon nanotubes. Toxicol Appl Pharmacol, 242: Lai D.Y., Sayre P.G. (2009). Toxicity Testing and Evaluation of Nanoparticles: Challenges in Risk Assessment. In: Nanotoxicology From In Vivo and In Vitro Models to Health Risks. (SC Sahu, DA Casciano, Eds.), Chapter 21, Wiley. Lai, D.Y.(2011). Toward Toxicity Testing of Nanomaterials in the 21 st Century: A Paradigm for Moving Forward. WIREs Nanomed Nanobiotechnol doi: /wnan.162 Poma A, DiGiorgi ML, (2008). Toxicogenomics to improve comprehension of the mechanisms underlying responses of in vitro and in vivo systems to nanomaterials: A review. Current Genomics, 9: Rollo R, France B, Liu R, et al., (2011). Self-organizing map analysis of toxicity-related cell signaling pathways for metal and metal oxide nanoparticles. Environ Sci Tech. 45: Witzmann FA, Monteiro-Riviere NA. (2006). Multi-walled carbon nanotube exposure alters protein expression in human kerotinocytes. Nanomedicine, 2: